News
Shares in Titanium and zircon miner Kenmare Resources fell today after it said it had terminated offer talks with a ...
At present, Russia and China dominate the global race for hypersonic missiles, with three advanced systems each.
The diversification into the HMS sector has its long-term advantages. Heavy mineral sand mines mainly target titanium and zirconium minerals like ilmenite, rutile and zircon, and also produce a ...
For centuries, the African continent has been an object of special interest for Western powers. Its rich subsoil, fertile ...
2d
Stockhead on MSNClosing Bell: ASX bets on July rate cut as employment data landsThe ASX fell 0.09pc in trade today, but positive employment data lifted the likelihood of an interest rate cut in July.
1d
Bizcommunity.com on MSNSaps busts over 200 suspects for illegal mining-related offencesIn conducting its Vala Umgodi Operation, the South African Police Service (Saps) arrested 239 suspects throughout the country ...
2d
Stockhead on MSNResources Top 5: QMines grows precious metals position in central QueenslandQMines will expand its precious metals position in central Queensland through the acquisition of Mount Mackenzie gold and ...
Titanium minerals and zircon producer Kenmare Resources, which operates the Moma mine, in Mozambique, has terminated discussions with a consortium, comprising Oryx Global Partners and Michael Carvill, ...
1d
Stockhead on MSNResources Top 5: It’s ‘Up There Cazaly’ as gold drilling kicks off at Duke of YorkCazaly Resources has begun a 2000m RC drilling program at Duke of York prospect within the Goongarrie gold project in ...
3d
Stockhead on MSNLunch Wrap: ASX swings flat as iron ore drags and energy stocks sinkThe ASX opened lower, briefly clawed its way into positive territory during the first hour, but was flat by lunchtime in the ...
When a child, my parents sent me to a central western NSW farm to recover from glandular fever. In order to shake me off, ...
3d
Stockhead on MSNTop 10 at 11: ASX dips in early trade; Amplia achieves second pancreatic cancer complete responseASX slips 0.16pc as tech and materials sectors lag. Amplia Therapeutics reports a second complete response in its pancreatic cancer trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results